IL-6 Inhibition as a Treatment for Noninfectious Uveitis - Takeaways - MDSpire

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

Understanding interleukin-6 signaling sheds light on novel biologics that could benefit patients with refractory NIU.

  • By

  • Naveen Karthik, MD

  • Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

  • 12 min

Share

  • 1

    Interleukin-6 (IL-6) is a proinflammatory cytokine involved in signaling pathways that promote inflammation in noninfectious uveitis (NIU).

  • 2

    Therapeutic agents targeting IL-6, including monoclonal antibodies, are being studied for their efficacy in treating refractory NIU.

  • 3

    Tocilizumab has shown significant efficacy in improving visual acuity and reducing macular edema in patients with refractory NIU.

  • 4

    Sarilumab demonstrated a significant decrease in vitreous haze and improved visual outcomes in patients with non-infectious uveitis.

  • 5

    Other IL-6 inhibitors, such as olokizumab and clazakizumab, are under investigation for their potential benefits in treating autoimmune conditions.

Original Source(s)

IL-6 Inhibition as a Treatment for Noninfectious Uveitis

  • by Naveen Karthik, MD, Dilraj S. Grewal, MD, FASRS

  • September 1, 2025

Related Content

Clinical Trial Update May/June 2026

Access Retinal Physician's listing of all active clinical trials in AMD, DME, RVO, and uveitis.

  • May 1, 2026

  • 44 min
New Tools for Imaging Retinal Inflammation

At ARVO 2026, Ethan A. Rossi, PhD, presented data on multimodal AOSLO imaging of immune cells in the living eye.

Why Uveitis Fellowship Deserves a Second Look

Uveitis Corner: Survey data and specialist insights challenge long-standing misconceptions about uveitis training, surgery, and compensation.